Literature DB >> 19017261

New insights into the molecular mechanisms of the fibrinolytic system.

D C Rijken1, H R Lijnen.   

Abstract

Fibrinolysis is regulated by specific molecular interactions between its main components. Activation of plasminogen by tissue-type plasminogen activator (t-PA) is enhanced in the presence of fibrin or at the endothelial cell surface. Urokinase-type plasminogen activator (u-PA) binds to a specific cellular u-PA receptor (u-PAR), resulting in enhanced activation of cell-bound plasminogen. Inhibition of fibrinolysis occurs at the level of plasminogen activation or at the level of plasmin. Assembly of fibrinolytic components at the surface of fibrin results in fibrin degradation. Assembly at the surface of cells provides a mechanism for generation of localized cell-associated proteolytic activity. This review includes novel proteins such a thrombin-activatable fibrinolysis inhibitor (TAFI) and discusses new insights into molecular mechanisms obtained from the rapidly growing knowledge of crystal structures of proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017261     DOI: 10.1111/j.1538-7836.2008.03220.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  84 in total

1.  Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro.

Authors:  Katherine A Ahmann; Justin S Weinbaum; Sandra L Johnson; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2010-10       Impact factor: 3.845

2.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

3.  A general method for detecting protease activity via gelation and its application to artificial clotting.

Authors:  Steven C Bremmer; Jing Chen; Anne J McNeil; Matthew B Soellner
Journal:  Chem Commun (Camb)       Date:  2012-04-27       Impact factor: 6.222

4.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

5.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

Review 6.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

Review 7.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 8.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 9.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

10.  Dual function of a bee venom serine protease: prophenoloxidase-activating factor in arthropods and fibrin(ogen)olytic enzyme in mammals.

Authors:  Young Moo Choo; Kwang Sik Lee; Hyung Joo Yoon; Bo Yeon Kim; Mi Ri Sohn; Jong Yul Roh; Yeon Ho Je; Nam Jung Kim; Iksoo Kim; Soo Dong Woo; Hung Dae Sohn; Byung Rae Jin
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.